DE60208534D1 - Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle - Google Patents

Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle

Info

Publication number
DE60208534D1
DE60208534D1 DE60208534T DE60208534T DE60208534D1 DE 60208534 D1 DE60208534 D1 DE 60208534D1 DE 60208534 T DE60208534 T DE 60208534T DE 60208534 T DE60208534 T DE 60208534T DE 60208534 D1 DE60208534 D1 DE 60208534D1
Authority
DE
Germany
Prior art keywords
treatment
antibody against
ischemic attacks
mag
against mag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60208534T
Other languages
English (en)
Other versions
DE60208534T2 (de
Inventor
Elaine Alison Irving
Mary Vinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60208534D1 publication Critical patent/DE60208534D1/de
Application granted granted Critical
Publication of DE60208534T2 publication Critical patent/DE60208534T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
DE60208534T 2001-02-08 2002-02-08 Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle Expired - Lifetime DE60208534T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0103174.9A GB0103174D0 (en) 2001-02-08 2001-02-08 Novel method of treatment
GB0103174 2001-02-08
PCT/GB2002/000551 WO2002062383A2 (en) 2001-02-08 2002-02-08 Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases

Publications (2)

Publication Number Publication Date
DE60208534D1 true DE60208534D1 (de) 2006-03-30
DE60208534T2 DE60208534T2 (de) 2006-11-30

Family

ID=9908386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60208534T Expired - Lifetime DE60208534T2 (de) 2001-02-08 2002-02-08 Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle

Country Status (11)

Country Link
US (2) US20040170627A1 (de)
EP (2) EP1645285A3 (de)
JP (2) JP5005156B2 (de)
AT (1) ATE314861T1 (de)
AU (1) AU2002229928A1 (de)
CY (1) CY1105549T1 (de)
DE (1) DE60208534T2 (de)
DK (1) DK1357941T3 (de)
ES (1) ES2254655T3 (de)
GB (1) GB0103174D0 (de)
WO (1) WO2002062383A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
CA2525784C (en) * 2003-05-16 2019-04-09 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US5932542A (en) * 1995-06-27 1999-08-03 Research Foundation Of Cuny, Hunter College Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
EP1047449B1 (de) * 1997-10-28 2003-09-10 The University Of British Columbia Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
EP1030684A4 (de) * 1997-11-14 2004-09-15 Euro Celtique Sa Modifizierte antikörper mit verstärkter fähigkeit eine anti-idiotypische antwort auszulösen
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
US20040002790A1 (en) * 2002-06-28 2004-01-01 Paul Senn Sensitive devices and sensitive applications
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment

Also Published As

Publication number Publication date
EP1357941A2 (de) 2003-11-05
US20080014195A1 (en) 2008-01-17
EP1645285A3 (de) 2010-04-14
EP1357941B1 (de) 2006-01-04
AU2002229928A1 (en) 2002-08-19
US20040170627A1 (en) 2004-09-02
DK1357941T3 (da) 2006-05-01
ES2254655T3 (es) 2006-06-16
JP2004523538A (ja) 2004-08-05
ATE314861T1 (de) 2006-02-15
DE60208534T2 (de) 2006-11-30
JP5005156B2 (ja) 2012-08-22
JP2008291031A (ja) 2008-12-04
CY1105549T1 (el) 2010-07-28
GB0103174D0 (en) 2001-03-28
WO2002062383A3 (en) 2003-04-10
EP1645285A2 (de) 2006-04-12
WO2002062383A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
DK1385864T3 (da) Anti-VEGF-2-antistoffer
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
CY1110963T1 (el) Εξανθρωπισμενα αντισωματα που αναγνωριζουν πεπτιδιο βητα αμυλοειδους
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60228567D1 (de) Behandlung von hyperlipidämie
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
DE60029985D1 (de) Verwendung von neurophilin liganden zur behandlung von augenerkrankungen
ATE526954T1 (de) Atomoxetin zur behandlung von allergischer rhinitis und asthma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition